Explore the Agenda
7:30 am Check In & Morning Coffee
Leveraging Smarter Trial Design to Ensure Accurate Enrolment & Timely Treatment Delivery
8:30 am Panel Discussion: Navigating Patient Selection & Eligibility in Europe to Ensure Timely Access to Cell Therapies
- Examine the complexities of trial design across oncology and autoimmune indications, including comorbidities, inpatient requirements, and overlapping recruitment efforts
- Discuss the readiness of Europe’s academic and healthcare ecosystems, from educating rheumatologists and haematologists to training medical staff in managing CAR-T related toxicities
- Highlight strategies to streamline patient identification and enrolment, including earlier eligibility assessments and addressing barriers such as hospital capacity and fragile patient timelines
9:15 am Integrating TCR-T Therapies into Existing Standard of Care
- Outline a unique clinical trial design aimed at embedding TCR-T therapies within existing oncology treatment pathways
- Discuss how focused umbrella trial designs accelerate development of TCR-T product libraries
9:45 am Advancing Lymphodepletion-Free CAR-Ts to Transform Autoimmune Disease Treatment
- Examine how lymphodepletion impacts trial design, patient safety, and overall therapeutic outcomes in autoimmune indications
- Explore strategies to improve monitoring, immunogenicity assessment, and product development for lymphodepletion-free CAR-Ts
- Highlight emerging approaches to optimise persistence and efficacy without reliance on toxic preconditioning regimens
10:15 am Translating Precision Protein Delivery into the Clinic: Designing Trials for ED007’s Novel Immune-Activating Platform
- Present translational data supporting ED007’s CAR-guided delivery of proinflammatory immune sensor proteins into cancer cells
- Discuss how AI-engineered proteins convert tumours into inflammation hubs to engage both innate and adaptive immunity
- Outline clinical trial design strategies to evaluate safety, efficacy, and immune activation in solid tumours resistant to checkpoint inhibitors
10:45 am Morning Break & Networking
R&D Track
Innovaiton in Science
Innovating in Receptor Designs & Novel Targets to Increase Efficacy in Difficult Indications
11:30 am Advancing Next-Generation TCR Therapies Targeting ROPN1 to Address Triple-Negative Breast Cancer
- Introduce the rationale for targeting ROPN1 as a novel and tumour-specific antigen in TNBC
- Highlight how next-generation TCR engineering enhances specificity and potency against hard-to-treat solid tumours
- Discuss translational and clinical development plans to demonstrate safety, efficacy, and durable responses in TNBC patients
New Data
12:00 pm Development of TCR Technology Platforms for Cancer Immunotherapy
- Highlight how next-generation of single chain TCR can prevent mispairing
- Share preclinical insights showing the potential of engineered stimulatory PD-L1 signalling for solid tumour applications
- Showcase the platform of targeted transduction for nonactivated T-cells
Manufacturing Track
Realising Scale & Access
Overcoming Analytical Bottlenecks for Reliable Product Release
11:30 am Standardising CAR T-Cell Monitoring to Improve Clinical Insights & Translational Outcomes
- Highlight approaches to monitor CAR T-cells consistently during production and in patients
- Explore how monitoring informs therapy development, safety, and efficacy assessments
- Discuss the potential for standardised monitoring to guide clinical decisions and improve outcomes
Establishing Lasting Partnerships for Faster & Smoother Cell Therapy Manufacturing
12:00 pm Roundtable Discussion: Maximising Success with CDMOs to Scale Cell Therapy Manufacturing & Build Collaborative Partnerships
- Identify best practices for seamless tech transfer that preserve product quality and reduce costly delays
- Share lessons on building long-term partnerships that balance flexibility, scalability, and regulatory expectations
12:30 pm Lunch & Networking Break
1:30 pm CARKey: a CAR-T Platform to Mitigate Tumour Antigen Heterogeneity & On-Target-off Tumour Toxicity
- Development of CARKey platform technology with multireceptor targeting
- Identification of combinatorial target proteins through bioinformatic analysis
- Rapid and strategic development of clinical candidate
New Data
Leveraging Armouring & Combination Approaches to Overcome Solid Tumour Barriers & Unlock Durable Responses
2:00 pm STAb-T Cells: Bridging Cell Therapy & Bispecific Antibodies for Sustained Antitumour Immunity
- Explore how STAb-T cells combine the precision of cell therapy with the versatility of bispecific antibodies to achieve durable tumour control
- Highlight emerging preclinical data demonstrating their potential to enhance targeting breadth and induce sustained responses
2:30 pm Armouring Effector Cells Against Oxidative Stress to Enhance Function & Persistence of T-Cell Based Therapies
- Present preclinical findings demonstrating how oxidative stress armouring can protect TILs and maintain their antitumour activity
- Discuss how enhancing TIL resilience to oxidative damage could improve durability and therapeutic outcomes in solid tumours
Driving Lean Manufacturing to Reduce Costs & Accelerate Timelines
1:30 pm Panel Discussion: Manufacturing Leaner & More Affordably to Accelerate Cell Therapy Development in Europe
- Identify key cost drivers in cell therapy manufacturing and discuss practical strategies to reduce them without compromising quality
- Debate approaches to efficient scale-out and scale-up that enable broader patient access while meeting regulatory and quality standards
2:00 pm Driving Efficiency & Unlocking Scalability for PRAME Cell Therapy Manufacturing
- Anzu-cel is TCR T-cell therapy directed against PRAME, a target expressed in more than 50 cancers
- Scaling out efficiently: horizontal expansion to increase speed and throughput
- Preparing for commercial manufacturing through operational excellence
2:30 pm Non-Viral Gene-Edited Manufacturing to Advance TCR-T Therapies
- Non-viral gene-edited TCR gene integration for potent TCR-T cell therapies
- Scalable manufacturing inputs to support scale-out and reduce timelines to FIH products
- Enable scalable, cost-effective TCR-T therapy delivery to meet growing clinical demand
3:00 pm Afternoon Break
Highlighting In-Vivo CAR-T Therapies as a Novel Frontier for Scalable & Accessible Cell Therapies
3:30 pm Non Viral In-Vivo CAR – Engineering with Episomal DNA: The Next Frontier for Off-the-Shelf & Scalable Cell Therapy
- Creating a third path to in-vivo CAR-T
- Highlight emerging preclinical evidence demonstrating feasibility and efficacy
New Data
4:00 pm Advancing In-Vivo CAR-T Therapies through Adaptable Lipid Nanoparticle Delivery
- Explore a novel platform enabling adaptable lipid nanoparticle (LNP) delivery for in-vivo CAR-T applications
- Discuss how merging antibody and LNP technologies enhances targeting precision and delivery efficiency
New Data
4:30 pm Pre-Clinical & Clinical Data Supporting Development of ENaBL: A Nanobody-Targeted, Immune-Shielded Lentiviral Platform for In-Vivo Cell Reprogramming
- Key preclinical data supporting the engineered features of the ENaBL vector for T-cell reprogramming
- Present clinical data demonstrating the safety and efficiency of ENaBL’s in-vivo BCMA CAR-T reprogramming in patients with multiple myeloma
- Highlight key clinical outcomes on response rates, persistence, and safety profile compared to ex-vivo approaches